Learn how analytical methodologies can be used to identify RSV pre- and post-fusion proteins for vaccine development.
Moderna Inc. recorded a quarterly loss as vaccine sales waned and the company had an unexpected charge for a canceled ...
It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...
Moderna reported a wider loss than expected for the fourth quarter on Friday morning, and the drugmaker's sales forecast for ...
AIM Vaccine Co., Ltd., a leading PRC vaccine company, announced today that its independently developed mRNA RSV (respiratory syncytial virus) vaccine has recently been submitted for clinical trials to ...
In preclinical animal trials, third-party testing results showed that AIM Vaccine's mRNA RSV vaccine achieved significantly higher levels of specific IgG antibody titers, live-virus neutralizing ...
Influenza, COVID-19 and RSV are staples of the winter cold and flu season, but the measles, whooping cough and norovirus are ...
Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 ...
Early signs of whooping cough in adults look very much like a common cold, Dr. Loafman says. For the first week or so of ...
Moderna is revamping its digital team, eliminating 10% of roles under two digital departments, affecting about 50 employees, ...
Chief Executive Stephane Bancel says Moderna will work with the Trump administration. Moderna stock rose in midday trades.
Moderna ( NASDAQ: MRNA) Q4 2024 Earnings Conference Call February 14, 2025 8:00 AM ET Lavina Talukdar - Senior Vice President, Investor Relations Stephane Bancel - Chief Executive Officer Jamey Mock - ...